Maintenance therapy with second generation antipsychotics for bipolar disorder – A systematic review and meta-analysis

Journal of Affective Disorders

Volumn 213, Issue , 2017, Pages 138-150

  Lindström, Leif ^a   Lindström, Eva ^a   Nilsson, Mikael ^b,c   Höistad, Malin ^b,d  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b Swedish Council on Technology Assessment in Health Care   (Sweden)

^c MALMÖ UNIVERSITY   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Add on; Adjunct; Adjunctive; Aripiprazole; Combination; Depressive; Lithium; Long term; Manic; Mood stabilizers; Olanzapine; Quetiapine; Risperidone; Valproate; Valproic acid; Ziprasidone

Indexed keywords

ARIPIPRAZOLE; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; VALPROIC ACID; ZIPRASIDONE;

AKATHISIA; BIPOLAR DISORDER; DAYTIME SOMNOLENCE; FOLLOW UP; HUMAN; INSOMNIA; MAINTENANCE THERAPY; META ANALYSIS; MONOTHERAPY; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEDATION; SIDE EFFECT; TREMOR;

ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; HUMANS;

EID: 85013187204     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/j.jad.2017.02.012     Document Type: Review

References (46)

1. Altamura, A.C., Mundo, E., Dell'Osso, B., Tacchini, G., Buoli, M., Calabrese, J.R., Quetiapine and classical mood stabilizers in the long-term treatment of Bipolar Disorder: a 4-year follow-up naturalistic study. J. Affect. Disord. 110 (2008), 135–141.
2. Baldessarini, R.J., Tondo, L., Vazquez, G.H., Undurraga, J., Bolzani, L., Yildiz, A., Khalsa, H.M., Lai, M., Lepri, B., Lolich, M., Maffei, P.M., Salvatore, P., Faedda, G.L., Vieta, E., Tohen, M., Age at onset versus family history and clinical outcomes in 1,665 international bipolar-I disorder patients. World Psychiatry.: Off. J. World Psychiatr. Assoc. (WPA) 11 (2012), 40–46.
3. Bandelow, B., Sher, L., Bunevicius, R., Hollander, E., Kasper, S., Zohar, J., Möller, H.J., WFSBP Task Force on Mental Disorders in Primary Care, WFSBP Task Force on Anxiety Disorders, OCD and PTSD. Guidelines for the pharmacological treatment of anxiety disorders, obsessive[HYPHEN]compulsive disorder and posttraumatic stress disorder in primary care. Int. J. Psychiatry Clin. Pract. 16:2 (2012), 77–84.
4. Bauer, E.A., S3-Leitlinie zur Diagnostik und Therapie Bipolarer Störungen. 2012, DGBS (Deutsche Gesellschaft für Bipolare Störungen) and DGPPN (Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde), Germany http://www.leitlinie-bipolar.de/wp-content/uploads/2016/07/S3_Leitlinie-Bipolar_V1_8.pdf.
5. Bialer, M., Why are antiepileptic drugs used for nonepileptic conditions?. Epilepsia 53:Suppl 7 (2012), 26–33.
6. Bowden, C.L., Vieta, E., Ice, K.S., Schwartz, J.H., Wang, P.P., Versavel, M., Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. J. Clin. Psychiatry 71 (2010), 130–137.
7. Carlson, B.X., Ketter, T.A., Sun, W., Timko, K., McQuade, R.D., Sanchez, R., Vester-Blokland, E., Marcus, R., Aripiprazole in combination with lamotrigine for the long-term treatment of patients with bipolar I disorder (manic or mixed): a randomized, multicenter, double-blind study (CN138-392). Bipolar Disord. 14 (2012), 41–53.
8. Cipriani, A., Hawton, K., Stockton, S., Geddes, J.R., Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ (Clin. Res. Ed. ), 346, 2013, f3646.
9. FDA, 2012. Enrichment strategies for clinical trials to support approval of human drugs and biological products. 〈www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM332181.pdf〉.
10. Geddes, J.R., Calabrese, J.R., Goodwin, G.M., Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br. J. Psychiatry: J. Ment. Sci. 194 (2009), 4–9.
11. Goodwin, G.M., Haddad, P.M., Ferrier, I.N., Aronson, J.K., Barnes, T., Cipriani, A., Coghill, D.R., Fazel, S., Geddes, J.R., Grunze, H., Holmes, E.A., Howes, O., Hudson, S., Hunt, N., Jones, I., Macmillan, I.C., McAllister-Williams, H., Miklowitz, D.R., Morriss, R., Munafò, M., Paton, C., Saharkian, B.J., Saunders, K., Sinclair, J., Taylor, D., Vieta E2 Young, A.H., Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology. J. Psychopharmacol. 30:6 (2016), 495–553.
12. Grunze, H., Vieta, E., Goodwin, G.M., Bowden, C., Licht, R.W., Moller, H.J., Kasper, S., The world Federation of Societies of biological psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. World J. Biol. Psychiatry: Off. J. World Fed. Soc. Biol. Psychiatry. 14 (2013), 154–219.
13. Guyatt, G.H., Oxman, A.D., Vist, G.E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., Schunemann, H.J., Group, G.W., GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (Clin. Res. Ed.) 336 (2008), 924–926.
14. Guyatt, G.H., Oxman, A.D., Kunz, R., Brozek, J., Alonso-Coello, P., Rind, D., Devereaux, P.J., Montori, V.M., Freyschuss, B., Vist, G., Jaeschke, R., Williams, J.W. Jr., Murad, M.H., Sinclair, D., Falck-Ytter, Y., Meerpohl, J., Whittington, C., Thorlund, K., Andrews, J., Schunemann, H.J., GRADE guidelines 6. Rating the quality of evidence – imprecision. J. Clin. Epidemiol. 64 (2011), 1283–1293.
15. Guyatt, G.H., Oxman, A.D., Kunz, R., Woodcock, J., Brozek, J., Helfand, M., Alonso-Coello, P., Falck-Ytter, Y., Jaeschke, R., Vist, G., Akl, E.A., Post, P.N., Norris, S., Meerpohl, J., Shukla, V.K., Nasser, M., Schunemann, H.J., Group, G.W., GRADE guidelines: 8. Rating the quality of evidence—indirectness. J. Clin. Epidemiol. 64 (2011), 1303–1310.
16. Guyatt, G.H., Oxman, A.D., Kunz, R., Woodcock, J., Brozek, J., Helfand, M., Alonso-Coello, P., Glasziou, P., Jaeschke, R., Akl, E.A., Norris, S., Vist, G., Dahm, P., Shukla, V.K., Higgins, J., Falck-Ytter, Y., Schunemann, H.J., Group, G.W., GRADE guidelines: 7. Rating the quality of evidence – inconsistency. J. Clin. Epidemiol. 64 (2011), 1294–1302.
17. Guyatt, G.H., Oxman, A.D., Montori, V., Vist, G., Kunz, R., Brozek, J., Alonso-Coello, P., Djulbegovic, B., Atkins, D., Falck-Ytter, Y., Williams, J.W. Jr., Meerpohl, J., Norris, S.L., Akl, E.A., Schunemann, H.J., GRADE guidelines: 5. Rating the quality of evidence—publication bias. J. Clin. Epidemiol. 64 (2011), 1277–1282.
18. Guyatt, G.H., Oxman, A.D., Schunemann, H.J., Tugwell, P., Knottnerus, A., GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J. Clin. Epidemiol. 64 (2011), 380–382.
19. Guyatt, G.H., Oxman, A.D., Vist, G., Kunz, R., Brozek, J., Alonso-Coello, P., Montori, V., Akl, E.A., Djulbegovic, B., Falck-Ytter, Y., Norris, S.L., Williams, J.W. Jr., Atkins, D., Meerpohl, J., Schunemann, H.J., GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias). J. Clin. Epidemiol. 64 (2011), 407–415.
20. Keck, P.E. Jr., Calabrese, J.R., McQuade, R.D., Carson, W.H., Carlson, B.X., Rollin, L.M., Marcus, R.N., Sanchez, R., Aripiprazole Study, G., A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J. Clin. Psychiatry 67 (2006), 626–637.
21. Keck, P.E. Jr., Calabrese, J.R., McIntyre, R.S., McQuade, R.D., Carson, W.H., Eudicone, J.M., Carlson, B.X., Marcus, R.N., Sanchez, R., Aripiprazole Study, G., Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J. Clin. Psychiatry 68 (2007), 1480–1491.
22. Kroon, J.S., Wohlfarth, T.D., Dieleman, J., Sutterland, A.L., Storosum, J.G., Denys, D., de Haan, L., Sturkenboom, M.C., Incidence rates and risk factors of bipolar disorder in the general population: a population-based cohort study. Bipolar Disord. 15 (2013), 306–313.
23. Macfadden, W., Adler, C.M., Turner, N., Turkoz, I., Haskins, J.T., Alphs, L., Long-acting risperidone adjunctive to standard treatment in patients with bipolar disorder who are experiencing mood symptoms. Bipolar Disord., 11, 2009, 58.
24. Marcus, R., Khan, A., Rollin, L., Morris, B., Timko, K., Carson, W., Sanchez, R., Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study. Bipolar Disord. 13 (2011), 133–144.
25. Merikangas, K.R., Jin, R., He, J.P., Kessler, R.C., Lee, S., Sampson, N.A., Viana, M.C., Andrade, L.H., Hu, C., Karam, E.G., Ladea, M., Medina-Mora, M.E., Ono, Y., Posada-Villa, J., Sagar, R., Wells, J.E., Zarkov, Z., Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch. Gen. Psychiatry 68 (2011), 241–251.
26. NICE, The assessment and management of bipolar disorder in adults, children and young people in primary and secondary care. (National Clinical Guideline Number 185., )(Full guideline), 2014, The British Psychological Society and The Royal College of Psychiatrists UK.
27. Nordentoft, M., Mortensen, P.B., Pedersen, C.B., Absolute risk of suicide after first hospital contact in mental disorder. Arch. Gen. Psychiatry 68 (2011), 1058–1064.
28. Ösby, U., Westman, J., Hällgren, J., Gissler, M., Mortality trends in cardiovascular causes in schizophrenia, bipolar and unipolar mood disorder in Sweden 1987–2010. Eur. J. Public Health 26 (2016), 867–871.
29. Pfennig, A., Bschor, T., Falkai, P., Bauer, M., The diagnosis and treatment of bipolar disorder: recommendations from the current s3 guideline. Dtsch. Arzteblatt Int. 110 (2013), 92–100.
30. Quiroz, J.A., Yatham, L.N., Palumbo, J.M., Karcher, K., Kushner, S., Kusumakar, V., Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Biol. Psychiatry 68 (2010), 156–162.
31. Rybakowski, J.K., Response to lithium in bipolar disorder: clinical and genetic findings. ACS Chem. Neurosci. 5 (2014), 413–421.
32. SBU, Schizofreni – läkemedelsbehandling, patientens delaktighet och vårdens organisation. 2012, SBU, Stockholm, Sweden 〈http://www.sbu.se/contentassets/3908bd4317a1421fb091eae098b150bb/schizofreni_2012.pdf〉.
33. SBU, Underhållsbehandling med nyare antipsykotiska läkemedel vid bipolär sjukdom. 2015, SBU, Stockholm, Sweden 〈http://www.sbu.se/sv/publikationer/SBU-utvarderar/underhallsbehandling-med-nyare-antipsykotiska-lakemedel-vid-bipolar-sjukdom2/〉.
34. SBU, Utvärdering av metoder i hälso- och sjukvården. En handbok. 2015, SBU, Stockholm, Sweden.
35. Schaffer, A., Isometsa, E.T., Azorin, J.M., Cassidy, F., Goldstein, T., Rihmer, Z., Sinyor, M., Tondo, L., Moreno, D.H., Turecki, G., Reis, C., Kessing, L.V., Ha, K., Weizman, A., Beautrais, A., Chou, Y.H., Diazgranados, N., Levitt, A.J., Zarate, C.A. Jr., Yatham, L., A review of factors associated with greater likelihood of suicide attempts and suicide deaths in bipolar disorder: Part II of a report of the International Society for Bipolar disorders Task force on Suicide in Bipolar Disorder. Aust. N.Z. J. Psychiatry 49 (2015), 1006–1020.
36. Suppes, T., Vieta, E., Liu, S., Brecher, M., Paulsson, B., Maintenance treatment for patients with bipolar I disorder: results from a North American study of quetiapine in combination with lithium or divalproex (trial 127). Am. J. Psychiatry 166 (2009), 476–488.
37. Tohen, M., Ketter, T.A., Zarate, C.A., Suppes, T., Frye, M., Altshuler, L., Zajecka, J., Schuh, L.M., Risser, R.C., Brown, E., Baker, R.W., Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am. J. Psychiatry 160 (2003), 1263–1271.
38. Tohen, M., Chengappa, K.N.R., Suppes, T., Baker, R.W., Zarate, C.A., Bowden, C.L., Sachs, G.S., Kupfer, D.J., Ghaemi, S.N., Feldman, P.D., Risser, R.C., Evans, A.R., Calabrese, J.R., Relapse prevention in bipolar 1 disorder: 18-month comparison of olanzapine plus mood stabiliser v mood stabiliser alone. Br. J. Psychiatry 184 (2004), 337–345.
39. Tohen, M., Greil, W., Calabrese, J.R., Sachs, G.S., Yatham, L.N., Oerlinghausen, B.M., Koukopoulos, A., Cassano, G.B., Grunze, H., Licht, R.W., Dell'Osso, L., Evans, A.R., Risser, R., Baker, R.W., Crane, H., Dossenbach, M.R., Bowden, C.L., Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am. J. Psychiatry 162 (2005), 1281–1290.
40. Tohen, M., Calabrese, J.R., Sachs, G.S., Banov, M.D., Detke, H.C., Risser, R., Baker, R.W., Chou, J.C., Bowden, C.L., Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am. J. Psychiatry 163 (2006), 247–256.
41. Vieta, E., Suppes, T., Eggens, I., Persson, I., Paulsson, B., Brecher, M., Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J. Affect. Disord. 109 (2008), 251–263.
42. Vieta, E., Montgomery, S., Sulaiman, A.H., Cordoba, R., Huberlant, B., Martinez, L., Schreiner, A., A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder. Eur. Neuropsychopharmacol.: J. Eur. Coll. Neuropsychopharmacol. 22 (2012), 825–835.
43. Weisler, R.H., Cutler, A.J., Ballenger, J.C., Post, R.M., Ketter, T.A., The use of antiepileptic drugs in bipolar disorders: a review based on evidence from controlled trials. CNS Spectr. 11 (2006), 788–799.
44. Weisler, R.H., Nolen, W.A., Neijber, A., Hellqvist, A., Paulsson, B., Trial 144 Study Investigators, Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (trial 144: a randomized controlled study). J. Clin. Psychiatry 72 (2011), 1452–1464.
45. Yatham, L.N., Kennedy, S.H., Parikh, S.V., Schaffer, A., Beaulieu, S., Alda, M., O'Donovan, C., MacQueen, G., McIntyre, R.S., Sharma, V., Ravindran, A., Young, L.T., Milev, R., Bond, D.J., Frey, B.N., Goldstein, B.I., Lafer, B., Birmaher, B., Ha, K., Nolen, W.A., Berk, M., Canadian network for mood and anxiety treatments (CANMAT) and International Society for bipolar disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 15 (2013), 1–44.
46. Young, A.H., McElroy, S.L., Olausson, B., Paulsson, B., A randomised, placebo-controlled 52-week trial of continued quetiapine treatment in recently depressed patients with bipolar I and bipolar II disorder. World J. Biol. Psychiatry.: Off. J. World Fed. Soc. Biol. Psychiatry. 15 (2014), 96–112.